Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer

BACKGROUND: The phosphatidylinositol-3-kinase/mammalian target of rapamycin (PI3K/mTOR) pathway is commonly deregulated in human cancer, hence many PI3K and mTOR inhibitors have been developed and have now reached clinical trials. Similarly, CDKs have been investigated as cancer drug targets. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Beale, Gary, Haagensen, Emma J, Thomas, Huw D, Wang, Lan-Zhen, Revill, Charlotte H, Payne, Sara L, Golding, Bernard T, Hardcastle, Ian R, Newell, David R, Griffin, Roger J, Cano, Celine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5023777/
https://www.ncbi.nlm.nih.gov/pubmed/27529512
http://dx.doi.org/10.1038/bjc.2016.238

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5023777/
https://www.ncbi.nlm.nih.gov/pubmed/27529512
http://dx.doi.org/10.1038/bjc.2016.238

Ejemplares similares